Jim Cramer Explains Why Heavily Shorted Moderna (MRNA) Has Room to Run

Jim Cramer discussed the market's shift away from heavily shorted Moderna (MRNA) on the August 31 episode of Mad Money. He highlighted a major hedge fund, Situational Awareness, which had been betting against the company and was beginning to unwind its position. Cramer pointed out that Moderna had developed a vaccine for patients who had previously beaten melanoma, a breakthrough that had initially been doubted by skeptics.

The partnership with Merck allowed Moderna to co-develop a personalized cancer vaccine. Despite strong performance in oncology, Moderna continues to face challenges such as substantial net losses, high research expenditures, and execution risks in clinical programs. Institutional backing for the company has also decreased slightly, with 49 hedge funds holding stakes compared to 52 in the prior quarter.

However, Cramer argued that dismissing Moderna based solely on fading pandemic revenues overlooks the potential for commercial products to generate substantial profits as the company progresses with its pipeline.